Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market.
This is old news. After meta analysis published a year or two ago basically ended Avandia'a run. Prescriptions dropped overnight practiocally to basically nil. Actos picked up some of that market as did Januvia that came to the market around that time has the only remaining TZD now in Actos. While it might seem good in the short term, I suppose Takeda is sweating a bit now wondering the overall backklash or fallout by prescribers and patients. The pie is getting bigger but their sliver is shrinking. It'll probably hold on, but who knows. Takeda might also realize by this that they need to diversify, just in case....which brings us to byetta, byetta LAR (or whatever it'll be named), and Amylin Pharmaceuticals. This is the match that makes most sense. However, I know from personal communications from at least one Lilly high exec that they plan to put "significant", "priority for 2010".. resources toawrd the launch of once weekly..... COuld make for a nice bidding war for Amylin.